Ozoralizumab
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1].
Product Specifications
CAS Number
[1167985-17-2]
Product Name Alternative
ATN-103; PF-5230896
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ozoralizumab.html
Purity
99.80
Solubility
10 mM in DMSO
Smiles
[Ozoralizumab]
Molecular Weight
(38.43 kDa)
References & Citations
[1]Ishiwatari-Ogata C, et, al. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022 Feb 22;13:853008.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
039819-ML405 100 µL
Pdgfra, ID (Pdgfra, Platelet-derived growth factor receptor alpha, Alpha platelet-derived growth factor receptor, Alpha-type platelet-derived growth factor receptor, CD140 antigen-like family member A, Platelet-derived growth factor alpha receptor, CD140a) (MaxLight 405) discontinued
Ask
View Details MBS1309750-01 0.02 mg (E-Coli)
Recombinant Staphylococcus aureus RNA polymerase sigma factor sigS (sigS)
Ask
View Details